Crestal sinus lift combining recombinant human bone morphogenetic protein-2 with leukocyte- and platelet- rich fibrin as grafting material: A 1-year retrospective pilot trial

Abstract

Objectives This study aimed to assess the bone augmentation potential and safety of rhBMP-2/ACS combined with L-PRF in crestal sinus lift. Materials and Methods This study applied a retrospective study design. We recruited patients undergoing crestal sinus lifting in combination with rhBMP-2/ACS and L-PRF one year after implantation. The bone augmentation potential was radiographically assessed by measuring the height, volume, and cancellous density of newly formed bone. The safety of this grafting protocol was evaluated through self-reported complications. Results Fourteen implants were installed simultaneously following sinus membrane elevation. All 14 implants fulfilled the success criteria one year after implantation. No complications were reported by the subjects. The average gained bone height and average gained bone volume were 3.2 mm and 435.7 mm3, respectively. Cancellous bone density in the sagittal plane on cone beam computed tomography images was significantly lower than that in the coronal or transverse plane. Conclusions This grafting protocol showed promising bone augmentation ability and excellent safety in crestal sinus floor augmentation. Clinical Relevance The combination of rhBMP-2 and L-PRF provides a promising grafting protocol for maxillary sinus floor elevation. Clinical trial This study has been registered in ChiCTR (ChiCTR2200063426) on Sep. 6, 2022.